PROTOTYPE INSTRUMENTATION FOR GLUCOSE SENSOR

需要开发用于连续测量的可植入传感器。 糖尿病患者的血糖监测。我们开发了一种植入式 基于与氧偶联的固定化葡萄糖氧化酶的葡萄糖传感器 电极，并将传感器作为静脉植入物进行操作， 100多天的狗。我们的葡萄糖传感器目前拥有世界上 作为功能性植入物进行连续长期操作的记录 无需重新校准。我们也是第一个开发和使用 具有植入葡萄糖的植入式遥测和仪器， 氧气传感器 这些成就证明了持续、长期 使用植入式仪器和遥测技术检测葡萄糖 动物，但有必要开发一个小型仪器包， 供人类使用该软件包将包括低电流输入 能够操作所述传感器的放大器或恒电位器，所述传感器耦合 涉及遥测传输或数据存储和检索装置。为 长期应用，具有遥测功能的植入式仪器必须 包装在密封容器中。原型版本 这些集成设备必须在成本更高之前建造和测试， 大规模集成制造是合理的。 在这个修改后的第一阶段项目中，我们计划（1）开发完整的系统 和元器件功能规范，作为电路设计的基础 设计;（2）设计、构建和测试第一代台式版本 （3）设计、建造和测试第二代“可穿戴” （4）开发第一代集成系统 芯片电路原理图，完成第一轮电路性能测试 模拟这些研究将为芯片制造铺平道路， 与传感器的集成，以及在 动物在第二阶段进行。 拟定商业应用： 糖尿病的管理消耗了全国卫生保健总额的15% 支出，25%的医疗保健支出，并负责 在人力资源上的巨大的，难以估量的成本。这些成本可以降低 基本上通过改善血糖控制， 胰岛素替代，通过持续监测血液而成为可能 葡萄糖这里要设计的仪器和遥测包 是传感器实现的关键。有几百万人 糖尿病患者可以从中受益。

There is a need for development of implantable sensors for continuous monitoring of glucose in diabetes. We have developed an implantable glucose sensor based on immobilized glucose oxidase coupled to an oxygen electrode and have operated the sensor as an intravenous implant for over 100 days in dogs. Our glucose sensor currently holds the world's record for continuous, long-term operation as a functioning implant without recalibration. We were also the first to develop and use implantable telemetry and instrumentation with implanted glucose and oxygen sensors. These achievements demonstrate the feasibility of continuous, long-term sensing of glucose employing implanted instrumentation and telemetry in animals but it is necessary to develop a small instrumentation package for eventual human use. The package would include low-current input amplifiers or potentiostats capable of operating the sensors, coupled to telemetry transmission or data storage and retrieval devices. For long-term applications, implantable instrumentation with telemetry must be packaged in hermetically sealed containers. Prototype versions of these integrated devices must be built and tested before more costly large-scale integrated fabrication is justified. In this revised Phase I project we plan to (1) develop complete system and component functional specifications to serve as a basis for circuit design; (2) design, build and test a first generation benchtop version of the system; (3) design, build and test a second generation "wearable" version of the system; and (4) develop a first generation integrated circuit chip schematic and complete a first round of circuit performance simulations. These studies will prepare the way for chip fabrication, integration with the sensor, and extensive implantation studies in animals to be carried out in Phase II. PROPOSED COMMERCIAL APPLICATION: The management of diabetes consumes 15% of total national health care expenditures, 25% of MediCare expenditures, and is responsible for an enormous, untold cost in human resources. These costs could be reduced substantially by better blood glucose control resulting from improved insulin replacement, made possible by continuous monitoring of blood glucose. The instrumentation and telemetry package to be designed here is essential for sensor implementation. There are several million people with diabetes who could benefit.